Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of Depigoid Birch Pollen in atopic eczema with birch pollen sensitization
2007-004876-38Phase 2Completed
- Sponsor
- LETI Pharma
- Start
- Sep 2007
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of depigoid birch in atopic dermatitis (AD) and birch pollen allergy, sponsored by LETI Pharma. Primary endpoint: Type and frequency of adverse events. Started Sep 2007; status: completed.
02
Drugs
depigoid birch
03
Conditions
atopic dermatitis (AD)birch pollen allergy
Beyond the preview
Go deeper on 2007-004876-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004876-38.